Improving palbociclib adherence among women with metastatic breast cancer using a CONnected CUstomized Treatment Platform: A pilot study

Sadigh, Gelareh; Meisel, Jane L.; Byers, Kristina F.; Robles, Andrew; Serrano, Leslie; Jung, Olivia; Coleman, Debrua; Yeager, Katherine A.; Graetz, Ilana

doi:10.1177/10781552231161823

Cited by 1 publication

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Toxicity or adverse effects could be the main reasons. Some adherence barriers were observed in assessing palbociclib adherence: inconvenience to get prescription filled, forgetfulness, cost, and side effects (Sadigh et al, 2023). Despite these limitations from the information extracted from our data sources, our results are the beginning of future research in measuring CDK 4/ 6i adherence.…”

Section: Discussionmentioning

confidence: 90%

“…Based on these results, different interventions could be developed to enhance CDK4/6i adherence. A mobile health intervention was tested integrating a connected electronic adherence monitoring smartbox and automated texting alerts, resulting a palbociclib adherence of 95.8% ± 7.6% (Sadigh et al, 2023). Baseline, before the intervention, the reported barriers were inconvenience to get prescription filled, forgetfulness, cost, and side effects.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Digging in real-word electronic database for assessing CDK 4/6 inhibitors adherence in breast cancer patients from Romania

Turcu-Stiolica,

Udristoiu,

Subtirelu

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Introduction: It is imperative for patients to respect the prescribed treatments to achieve the anticipated clinical outcomes, including the outpatients receiving oral anti-cancer drugs such as selective cyclin-dependent kinase 4/6 inhibitors (CDK 4/6i). With the introduction of three CDK 4/6i drugs in the Romanian pharmaceutical market in 2018, our study aimed to evaluate medication adherence and the influencing factors among patients undergoing treatment with palbociclib, ribociclib, or abemaciclib for advanced or metastatic breast cancer.Methods: Medication adherence was assessed using the Proportion of Days Covered (PDC) method, and Spearman correlation analysis was conducted to explore the relationships between adherence, age, gender, and follow-up duration.Results: The study enrolled 330 breast cancer patients, with an average follow-up period of 14.6 ± 12.5 months for palbociclib, 10.6 ± 7.1 months for ribociclib, and 8.6 ± 6.4 months for abemaciclib-treated patients. A small proportion of patients demonstrated non-adherence: 12.8% for palbociclib, 14.6% for ribociclib, and 14.7% for abemaciclib. Among patients receiving palbociclib, there was no significant correlation between adherence, age (rho = 0.07, p = 0.35), or gender (rho = −0.144, p = 0.054). However, a significant correlation was found with the duration of follow-up (rho = −0.304, p < 0.0001). Similar results were observed for patients receiving ribociclib or abemaciclib. Most patients received combination therapy with letrozole (46%) and exemestane (13%) for palbociclib, letrozole (48%) and fulvestrant (19%) for ribociclib, and fulvestrant (39%) and letrozole (27%) for abemaciclib,Discussion: High adherence rates were observed among patients treated with CDK 4/6i drugs, with no significant differences noted among the three drugs in this class. However, the collected patient data was limited, lacking information on adverse reactions that could potentially lead to treatment discontinuation, as determined by the oncologist’s decision not to prescribe. Consequently, a comprehensive understanding of all factors contributing to the low adherence levels is hindered.

show abstract

Section: Discussionmentioning

confidence: 90%

Section: Discussionmentioning

confidence: 99%